To Our Shareholders
and Investors

• May 14, 2025

  R & D
  RGX-121 (clemidsogene lanparvovec) : The U.S. FDA has accepted the Biologics License Application by REGENXBIO for Mucopolysaccharidosis II Disease
• May 08, 2025

  Management & Finance
  Outline of Consolidated Financial Results for the Year Ended March 31, 2025
• April 18, 2025

  R & D
  FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
• March 28, 2025

  R & D
  Submission of New Drug Application for NS-401 (Tagraxofusp) in Japan

Upcoming Events

• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1 MB
• May 08, 2025
  FY2024 Annual results announcement PDF1.9 MB
• February 18, 2025
  R&D Meeting PDF1.7 MB
• February 07, 2025
  Conference Call(Q3/FY2024) PDF921 KB
• February 07, 2025
  FY2024 3rd Qtr results announcement PDF780 KB